Here are the S-3 shelf registrations from Kura Oncology, Inc. (KURA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow KURA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KURA filings page.
Kura Oncology, Inc. may offer common stock with an aggregate offering price of up to $150.0 million from time to time through Leerink Partners LLC and Cantor Fitzgerald & Co. as sales agents in at-the-market offerings. The agents are not required to sell a specified amount, and their compensation may be up to 3.0% of gross proceeds from shares sold. Kura intends to use net proceeds to support KOMZIFTI commercialization, advance its pipeline, and fund working capital and other general corporate purposes. In a dilution illustration, an assumed sale of 19,815,059 shares at $7.57 per share results in estimated immediate dilution of $6.10 per share. The illustration shows adjusted net tangible book value of approximately $164.7 million, or $1.47 per share, after the assumed sale.